- Global Pharma News & Resources

Bloom Science Announces Initiation of Microbiome Sample Collection Study in Subjects Implementing the Ketogenic Diet

Bloom Science Announces Initiation of Microbiome Sample Collection Study in Subjects Implementing the Ketogenic Diet

PR Newswire

SAN DIEGO, Oct. 4, 2018

SAN DIEGO, Oct. 4, 2018 /PRNewswire/ -- Bloom, targeting rare epileptic syndromes with orally-delivered pharmaceutical compositions of specific combined strains of naturally-occurring microbes, today announced the initiation of a microbiome sample collection study titled: Effects of the Ketogenic Diet on the Gut Microbiota.  

The study is open to individuals implementing the ketogenic diet and related low-carbohydrate diets, such as intermittent fasting. "The initiation of this study, which we are calling 'Poo for Epilepsy,' marks an important milestone in Bloom's translational research strategy, which is rooted in clinical data observations from diet, and our focus on understanding those metabolites, modulated by microbes in our gut, that are involved in disease prevention," said Christopher Reyes, Ph.D., CSO at Bloom Science.

Bloom is developing a new category of orally-administered GABAergic modulating therapeutics for neurological disease. Tony Colasin, CEO at Bloom Science, commented, "expanding our deep understanding and building our proprietary technology platform is important to advancing our business model, driving development decisions and supporting our global partnering strategy."   

The initiative has been endorsed by the Charlie Foundation, a leader in the field of advocating diet therapies for epilepsy, to raise awareness of the study through its network. "It is our hope that Bloom Science can uncover a link between the gut microbiome and seizures which will lead to a new therapy to help people with epilepsy," said Jim Abrahams, Charlie Foundation Co-Founder and Executive Director.

Individuals interested should visit to find more information about the study.

About Bloom Science
Bloom Science is a biotechnology discovery and development company creating a new class of neuroprotective medicines that seek to replicate the benefits of the ketogenic diet to improve quality of life for people with epilepsy and other neurological conditions.

11575 Sorrento Valley Road, #203
San Diego, CA 92121

Media Contact: Laura Tufts
DeLiGhT Communications


View original content to download multimedia:

SOURCE Bloom Science

Editor Details

Last Updated: 04-Oct-2018